Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Head and Neck

Volumn 33, Issue 9, 2011, Pages 1278-1284

  Yoldas, Burcak ^a   Ozer, Cem ^b   Ozen, Ozlem ^b   Canpolat, Tuba ^b   Dogan, Isilay ^b   Griffith, Thomas S ^c   Sanlioglu, Salih ^a   Ozluoglu, Levent N ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

clinical and pathologic staging; head and neck cancer; molecular diagnostics; TRAIL; TRAIL receptor

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RETROSPECTIVE STUDIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80051743553     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21598     Document Type: Article

References (35)

1. Griffith TS, Stokes B, Kucaba TA, et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9: 9-19.
2. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C,. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009; 4: 34-41.
3. Wang S,. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27: 6207-6215.
4. Ashkenazi A, Holland P, Eckhardt SG,. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-3630.
5. Wu GS,. TRAIL as a target in anti-cancer therapy. Cancer Lett 2009; 285: 1-5.
6. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A,. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-288.
7. Elrod HA, Sun SY,. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008; 7: 163-173. (Pubitemid 351590418)
8. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG,. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-820. (Pubitemid 28064894)
9. Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ,. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004; 11: 681-690. (Pubitemid 39299208)
10. Ren X, Xu Z, Myers JN, Wu X,. Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. Cancer Biol Ther 2007; 6: 1031-1035. (Pubitemid 351574953)
11. Sanlioglu AD, Koksal T, Baykara M, Luleci G, Karacay B, Sanlioglu S,. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Gene Ther Mol Biol 2003; 7: 113-133.
12. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S,. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54 (abstract).
13. Aydin C, Sanlioglu AD, Karacay B, et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 2007; 18: 39-50. (Pubitemid 46105463)
14. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S,. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 2007; 14: 976-984. (Pubitemid 350115354)
15. Terzioglu E, Bisgin A, Sanlioglu AD, et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 783-789. (Pubitemid 47061708)
16. Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB,. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 2004; 57: 595-602. (Pubitemid 40348040)
17. Pai SI, Wu GS, Ozoren N, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998; 58: 3513-3518. (Pubitemid 28376541)
18. Fisher MJ, Virmani AK, Wu L, et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001; 7: 1688-1697. (Pubitemid 32708637)
19. Almadori G, Bussu F, Cadoni G, et al. Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review. Eur J Cancer 2004; 40: 2383-2388. (Pubitemid 39424950)
20. Manual. AJCoCACS, 6th ed. New York: Springer; 2002. pp 47-57.
21. Fleming ID,. AJCC/TNM cancer staging, present and future. J Surg Oncol 2001; 77: 233-236. (Pubitemid 32744190)
22. Sanlioglu AD, Dirice E, Elpek O, et al. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008; 36: 385-893.
23. Sanlioglu AD, Dirice E, Elpek O, et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009; 38: 154-160.
24. Sanlioglu AD, Korcum AF, Pestereli E, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 716-723. (Pubitemid 47418395)
25. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S,. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol 2007; 177: 359-364. (Pubitemid 44879477)
26. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S,. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006; 13: 21-31. (Pubitemid 41816346)
27. Wu F, Hu Y, Long J, et al. Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells. Oncol Rep 2009; 21: 461-465.
28. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S,. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26: 158-165. (Pubitemid 351288560)
29. Vigneswaran N, Baucum DC, Wu J, et al. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 2007; 7: 108 (abstract).
30. Dirice E, Sanlioglu AD, Kahraman S, et al. Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum Gene Ther 2009; 20: 1177-1189.
31. Cheung SS, Metzger DL, Wang X, et al. Tumor necrosis factor-related apoptosis-inducing ligand and CD56 expression in patients with type 1 diabetes mellitus. Pancreas 2005; 30: 105-114. (Pubitemid 40289448)
32. Sanlioglu AD, Griffith TS, Omer A, et al. Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes. J Cell Biochem 2008; 104: 710-720. (Pubitemid 351830823)
33. Trauzold A, Siegmund D, Schniewind B, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 25: 7434-7439. (Pubitemid 44853434)
34. Kassouf N, Thornhill MH,. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers. Oral Oncol 2008; 44: 672-682. (Pubitemid 351842819)
35. Teng MS, Brandwein-Gensler MS, Teixeira MS, Martignetti JA, Duffey DC,. A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2005; 131: 407-412. (Pubitemid 40638144)